首页> 外文期刊>Journal of Clinical Pathology >Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods
【24h】

Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods

机译:组织蛋白酶D在乳腺癌中的预后价值:免疫组织化学和免疫放射检测方法的比较

获取原文
获取原文并翻译 | 示例
       

摘要

Aim-To test whether immunoradiometric or immunohistochemical detection of lysosomal protease cathepsin D in breast cancer is more predictive of outcome. Methods-Tumour tissues from 270 primary breast cancer patients were evaluated for the expression of cathepsin D using immunohistochemistry (IH; paraffin embedded tissues) and an immunoradiometric assay (IRMA; cytosol from frozen tissues). Immunohistochemical scores were based on immunoreaction in tumour cells and tumour associated macrophages. Results-IRMA values (cut off 40 fmol/mg cell protein) correlated significantly with IH values. Recorded incidences of positive immunoreaction in tumour cells using two different cut off values were 52% and 35%, respectively. Macrophages stained positive in 31% of tissues. Combined evaluation of tumour cells and macrophages resulted in positivity rates of 59% and 48%, respectively. Node status was the only variable found to correlate with cathepsin D expression. IH results correlated significantly with clinical outcome (median observation time 68 months) in node negative patients (n=120) but not in node positive patients (n=145). Cathepsin D positivity as measured by IRMA was not related to clinical outome in either group. On multivariate analysis in the node negative group, IH detection of cathepsin D appeared to be the only independent factor indicating prognosis. For node positive patients, tumour grade, size, and receptor status were of prognostic relevance. Conclusions-Because of the simple methodology and the minimal amount of tissue used for analysis, immunohistochemistry was preferred to immuno-radiometry for cathepsin D measurement; it also provided more predictive data with respect to prognosis.
机译:目的-测试乳腺癌中溶酶体蛋白酶组织蛋白酶D的免疫放射测定或免疫组织化学检测是否更能预测结果。方法-使用免疫组织化学(IH;石蜡包埋组织)和免疫放射测定法(IRMA;冷冻组织中的细胞溶质)评估了270例原发性乳腺癌患者的肿瘤组织中组织蛋白酶D的表达。免疫组织化学评分基于肿瘤细胞和肿瘤相关巨噬细胞的免疫反应。结果-IRMA值(截断40 fmol / mg细胞蛋白)与IH值显着相关。使用两个不同的临界值记录的肿瘤细胞中阳性免疫反应的发生率分别为52%和35%。巨噬细胞在31%的组织中染色呈阳性。肿瘤细胞和巨噬细胞的综合评估分别使阳性率分别为59%和48%。节点状态是唯一发现与组织蛋白酶D表达相关的变量。 IH结果与淋巴结阴性患者(n = 120)的临床结果(中位观察时间为68个月)显着相关,而与淋巴结阳性患者(n = 145)无关。两组均通过IRMA测定的组织蛋白酶D阳性与临床结果无关。在结节阴性组的多变量分析中,组织蛋白酶D的IH检测似乎是指示预后的唯一独立因素。对于淋巴结阳性患者,肿瘤等级,大小和受体状态与预后相关。结论-由于使用简单的方法和最少的组织进行分析,免疫组织化学比免疫放射法更适合用于组织蛋白酶D的测量;它还提供了有关预后的更多预测数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号